Drugs · Brain health technique
Methylene Blue / LMTM (Leuco-Methylthioninium)
Evidence grade: Experimental
A redox-active compound with mitochondrial and tau-modulating effects, historically used as a dye and in methemoglobinemia. Investigational formulations include methylene blue (USP form) and its derivative LMTM (TauRx Therapeutics), studied for Alzheimer’s and cognitive decline.
- Practice
- Drugs
- Principle
- Treatment
- Tactic
- Neuroprotective & Disease-modifying Therapies
- Evidence grade
- Experimental
- Strength of evidence
- Low
- Cost
- High
- Effort
- Low
- Time commitment
- Low
How to practice Methylene Blue / LMTM (Leuco-Methylthioninium)
Only to be used under clinical supervision or in research contexts. Low-dose regimens (≤2 mg/kg) appear safe but not evidence-based for cognitive outcomes. Avoid self-administration and drug interactions with serotonergic agents. Await next-generation tau-targeted redox compounds for validated efficacy.
The evidence behind Methylene Blue / LMTM (Leuco-Methylthioninium)
Mechanism involves enhanced mitochondrial respiration, reduced oxidative stress, and inhibition of tau aggregation. Early small trials showed mild cognitive benefits, but large phase 3 trials (MADE, LUCIDITY) failed primary endpoints. Evidence mixed: biological plausibility remains high, but clinical benefit remains unproven. Risks include serotonin syndrome with SSRIs or MAOIs at high doses.
More Drugs techniques
Take control of your brain health
BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.